The BM-MSCs IT injection in OVA-induced asthma decreased eosinophilia, lymphocyte, total protein, IL-13, and IL-17A levels and significantly decreased airway remodeling, which persisted for 14 days after the injection (Boldrini-Leite et al., 2020). This evidence concerns the gene IL17A and asthma.